StreetInsider.com News Articles

Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026

Wed, 14 Oct 2026 16:30:00 -0400

REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) today announced that the Company will release interim clinical data related to its tagmokitug development program evaluating the cytolytic CCR8 antibody with toripalimab and multiple solid tumors on Wednesday, October 28, 2026. Coherus management will host a webcast from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time to discuss the data and provide additional context. The company has invited key opinion leaders to join the webcast and provide their clinical perspective.

Webcast Information

When: Wednesday, October 28, 2026, from 4:30 p.m. to

Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026

Wed, 14 Oct 2026 16:30:00 -0400

Webcast Information

When: Wednesday, October 28, 2026, from 4:30 p.m. to

Coherus Oncology hires Oppenheimer to sell biosimilar assets

Wed, 23 Sep 2026 09:31:17 -0400

Coherus Oncology, Inc. (NASDAQ: CHRS) has retained Oppenheimer & Co. Inc. as its financial advisor to market and sell the remaining assets from its former biosimilars business, according to a press release issued Sept. 23, 2026.

The assets being marketed, referred to as the Legacy BioSim Assets, include patents and other intellectual property, royalties under an existing license agreement, cell lines, and related materials such as laboratory notebooks, regulatory filings, and product samples.

Denny Lanfear, President and Chief Executive Officer of Coherus, said: "We are pleased to be working with a bank of Oppenheimer's caliber to market our legacy biosimilars assets. We

Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets

Wed, 23 Sep 2026 09:30:00 -0400

REDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that it has initiated the process to market and sell the remaining assets associated with the Company’s former biosimilars business (the “Legacy BioSim Assets”). The Company has retained Oppenheimer & Co. Inc. (“Oppenheimer”) to serve as its financial advisor in connection with the sale. Parties interested in the opportunity should direct inquiries to the Oppenheimer contacts listed below.

“We are pleased to be working with a bank of Oppenheimer’s caliber to market our legacy biosimilars assets,” said Denny Lanfear,

Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets

Wed, 23 Sep 2026 09:30:00 -0400

“We are pleased to be working with a bank of Oppenheimer’s caliber to market our legacy biosimilars assets,” said Denny Lanfear,

Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets

Wed, 23 Sep 2026 09:30:00 -0400

- Oppenheimer Initiates a Robust Process with Global Reach for the Benefit of Shareholders -

“We are pleased to be working with

Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets

Wed, 23 Sep 2026 09:30:00 -0400

- Oppenheimer Initiates a Robust Process with Global Reach for the Benefit of Shareholders -

“We are pleased to be working with

Coherus to Participate in Upcoming Investor Conferences

Mon, 31 Aug 2026 09:30:00 -0400

REDWOOD CITY, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be participating in upcoming investor conferences:

Baird 2026 Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 7:55 a.m. Eastern Daylight Time.
H.C. Wainwright 28^th Annual Global Investment Conference in New York, NY on Tuesday, September 15, 2026, at 11:30 a.m. Eastern Daylight Time.
Morgan Stanley 24^th Annual Global Healthcare Conference in New York, NY on Wednesday, September 16, 2026, at 12:20 p.m. Eastern Daylight

Coherus to Participate in Upcoming Investor Conferences

Mon, 31 Aug 2026 09:30:00 -0400

REDWOOD CITY, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be participating in upcoming investor conferences:

Baird 2026 Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 7:55 a.m. Eastern Daylight Time.
H.C. Wainwright 28^th Annual Global Investment Conference in New York, NY on Tuesday, September 15, 2026, at 11:30 a.m. Eastern Daylight Time.
Morgan Stanley 24^th Annual Global Healthcare Conference in New York, NY on Wednesday, September 16, 2026, at 12:20 p.m. Eastern Daylight

Form 8-K Coherus Oncology, Inc. For: Aug 28

Fri, 28 Aug 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260828/26999031.html

Form 8-K Coherus Oncology, Inc. For: Aug 28

Fri, 28 Aug 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260828/26999031.html

Form 424B5 Coherus Oncology, Inc.

Fri, 28 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260828/26998578.html

Form 424B5 Coherus Oncology, Inc.

Fri, 28 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260828/26998578.html

Form 424B3 Coherus Oncology, Inc.

Fri, 28 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260828/26998549.html

Form 424B3 Coherus Oncology, Inc.

Fri, 28 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260828/26998549.html

Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights

Mon, 17 Aug 2026 17:33:00 -0400